Onconova Therapeutics has formed a strategic collaboration to use Mission Bio’s Tapestri platform for targeted single-cell DNA analysis in order to study its novel cancer therapy, rigosertib, through clinical trials.
Precision biomarkers, which are needed due to increased complexity of clinical trials, save time and cost linked with the drug development cycle.
Technologies such as broad-based sequencing cannot identify the earlier single cell events containing driver mutations that initiate the oncologic disease.
The Tapestri platform enables researchers to detect rare cancer subclones and co-occuring cancer mutations at the single-cell level. It provides a better way to measure therapy response and progression of disease.
Mission Bio CCO Darrin Crisitello said: “Through single-cell genomics, we can identify mutations with far better resolution than that of traditional sequencing methods. This allows a view into each patient’s disease at a level never before achieved.
“The Tapestri Platform can identify subclones that help monitor a patient’s response to research drugs in clinical trials, supporting the advancement of rigosertib to the clinic.”
Onconova CEO Steve Fruchtman said: “Rigosertib has the potential to be the first new higher-risk MDS treatment in more than 15 years, for a condition affecting an estimated 59,000 patients with low and higher-risk MDS in the United States alone.
“In adding the Tapestri Platform to our research and development program, we are including the opportunity to study single cell clones in MDS and determine the sequence of genetic events and the influence of rigosertib on these events along with clinical outcomes.
Onconova Therapeutics is a clinical-stage biopharmaceutical company that discovers and develops novel products to treat cancer, with primary focus on Myelodysplastic Syndromes (MDS).
US-based Mission Bio develops and delivers tools for the study of cellular heterogeneity. Mission Bio supports pharma and biopharma industries through the commercialisation of clinical trials.